Atopic Dermatitis | Emerging Therapies | Eucrisa (crisaborole) | US | Wave 1 | 2017
Atopic Dermatitis | Emerging Therapies | Eucrisa | USis a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.
What you will learn in this content:
- What is U.S. dermatologists’ awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
- Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
- What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?
Methodology: ~75-100 U.S. dermatologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.
Key drugs: Eucrisa
Key companies: Pfizer
Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU)
